ArticleMedicine2026
Exploring the causal relationship between COPD and AKI: A bidirectional Mendelian randomization approach.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Chronic obstructive pulmonary disease (COPD) and acute kidney injury (AKI) are significant public health burdens, and emerging observational studies have suggested a potential link between them. However, causality remains unclear. This study aimed to investigate the causal relationship between COPD and AKI using two-sample Mendelian randomization (MR) analyses. We utilized 11 independent single-nucleotide polymorphisms associated with COPD to perform two-sample MR analyses on 2 AKI datasets (GCST90018790 and ACUTERENFAIL). Inverse variance weighted (IVW), weighted median, MR-Egger, and weighted mode methods were employed to estimate causal effects. Sensitivity analyses included MR-Egger intercept tests for directional pleiotropy and Cochran Q tests for heterogeneity. A reverse MR analysis was also conducted using 9 AKI-associated single-nucleotide polymorphisms to assess the potential causal effect of AKI on COPD. IVW analysis indicated a significant causal effect of genetically predicted COPD on increased risk of AKI in both GCST90018790 (odds ratio [OR] = 1.28, 95% confidence interval [CI]: 1.13-1.46, P = 1.19 × 10-4) and ACUTERENFAIL (OR = 1.23, 95% CI: 1.02-1.48, P = .031) datasets. The weighted median method supported these findings in the GCST90018790 dataset. No significant pleiotropy or heterogeneity was detected across sensitivity analyses. In contrast, reverse MR analyses did not reveal a causal effect of AKI on COPD (IVW OR = 0.99, 95% CI: 0.94-1.04, P = .70), with consistent null results across all methods and no evidence of pleiotropy or heterogeneity. Our findings provide genetic evidence supporting a potential causal effect of COPD on increased risk of AKI, but not vice versa. Our results suggest that COPD liability is consistent with an increased propensity for AKI, warranting further exploration of potential biological mechanisms linking pulmonary and renal dysfunction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.